Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Genetic Technologies Ltd Receives Certification For New York State


Thursday, 29 Aug 2013 07:26pm EDT 

Genetic Technologies Ltd announced that it has received its Clinical Laboratory Permit from the New York State Department of Health (DoH). In late July, the Company‚Äôs Melbourne laboratories were inspected under New York's DoH Clinical Laboratory Evaluation Program (CLEP) and, following the two-day audit, it subsequently received a Laboratory Evaluation Report with 'No significant deficiencies'. Thus, the permit was able to be issued immediately. This permit allows the Company to test BREVAGen from residents of New York State - a densely populated state of nearly 20 million people - and completes the out of state licensures allowing the Company to provide testing services to all 50 US states. The Company can now meet requests received from New York physicians to provide the BREVAGenTM test to patients as part of their clinical practice. Phenogen Sciences Inc. (Genetic Technologies' US subsidiary) will be appointing representatives in the near future to cover this state, with a particular emphasis on New York City. 

Company Quote

0.017
0.0020 +13.33%
21 Oct 2014